Seravue® (Diagnostic Assay)
Hepatocellular Carcinoma (HCC)
DevelopmentActive
Key Facts
About ImCare Biotech
ImCare Biotech is a US-based, private biotech company founded in 2011, targeting liver cancer and related diseases through a dual approach of diagnostics and small molecule therapeutics. The company is in the pre-clinical/development stage, leveraging a management team with strong scientific and commercial expertise from institutions like Drexel University, McKinsey, and Cisco. Its core focus is on translating proprietary research into commercial diagnostic assays and drugs, with a clear vision to become a global leader in liver disease management.
View full company profileTherapeutic Areas
Other Hepatocellular Carcinoma (HCC) Drugs
| Drug | Company | Phase |
|---|---|---|
| ADI-PEG 20 (pegargiminase) | Polaris Pharma | Phase 2/3 |
| Fostroxacitabine bralpamide (MIV-818) | Medivir | Phase 2a |
| YntraDose | BetaGlue Therapeutics | Pre-clinical |
| AD2C-Oncology (GPC3) | Acepodia | Preclinical |
| seRNA 001 | SRTD biotech | Preclinical |
| ZW251 | Zymeworks | Phase 1 |
| TTI-101 | Tvardi Therapeutics | Phase 1b/2 |